CCXI Share Price

Open 6.70 Change Price %
High 6.74 1 Day -0.07 -1.05
Low 6.50 1 Week 0.00 0.00
Close 6.57 1 Month -1.32 -16.73
Volume 96097 1 Year -1.48 -18.39
52 Week High 10.80
52 Week Low 6.13
CCXI Important Levels
Resistance 2 6.79
Resistance 1 6.70
Pivot 6.60
Support 1 6.44
Support 2 6.35
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
MU 44.31 6.39%
MU 44.31 6.39%
RIMM 13.03 0.39%
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%

ChemoCentryx, Inc. (NASDAQ: CCXI)

CCXI Technical Analysis 5
As on 31st Oct 2017 CCXI Share Price closed @ 6.57 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 7.64 & Strong Sell for SHORT-TERM with Stoploss of 7.26 we also expect STOCK to react on Following IMPORTANT LEVELS.
CCXI Target for May
1st Target up-side 7.71
2nd Target up-side 8.52
3rd Target up-side 9.32
1st Target down-side 5.43
2nd Target down-side 4.62
3rd Target down-side 3.82
CCXI Other Details
Segment EQ
Market Capital 452141184.00
Sector Healthcare
Industry Biotechnology
Offical website
CCXI Address
850 Maude Avenue
Mountain View, CA 94043
United States
Phone: 650-210-2900
Fax: 650-210-2910
CCXI Latest News
Interactive Technical Analysis Chart ChemoCentryx, Inc. ( CCXI NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on ChemoCentryx, Inc.
CCXI Business Profile
ChemoCentryx is a biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The Company targets the chemokine system, a network of molecules, including chemokine ligands and their associated receptors, as well as related chemo-attractant receptors, all of which are known to drive inflammation. As of December 31, 2011, the Company had four drug candidates in clinical development. Its drug candidates include Traficet-EN (CCX282, GSK'786 or vercirnon), CCX140, CCX354, CCX168, CCX872, CCX507 and CCX662. The Company is also advancing several additional independent drug candidates through preclinical development. The Company’s wholly owned subsidiary is ChemoCentryx Limited. The Company's drug candidate Traficet-EN (CCX282, GSK'786), is to control the inflammatory response underlying IBD by targeting the chemokine receptor known as CCR9. The Company has completed nine clinical trials with Traficet-EN in a total of 785 subjects, including five Phase I clinical trials (three in the United States and two in the United Kingdom), one thorough QT study in the United States (an assessment of cardiovascular safety which is required for regulatory approval), and three Phase II clinical trials (one in the Netherlands, the United Kingdom, and the United States, one in Finland and one (PROTECT-1) in Australia, Austria, Belgium, Brazil, Bulgaria, Canada, the Czech Republic, Denmark, France, Germany, Hungary, Israel, the Netherlands, Poland, South Africa, Sweden and the United Kingdom). As of December 31, 2011, the Company’s Traficet-EN drug candidate is in four pivotal Phase III clinical trials being conducted by its partner Glaxo Group Limited (GSK). The Company's independent drug candidate CCX140, targets the chemokine receptor known as CCR2. CCX140 is a potent and selective antagonist of CCR2 that is found on subsets of monocytes and macrophages, which are cells of the immune system. In January 2011, the Company completed a 159-patient randomized Phase II clinical trial, conducted in Australia, the Czech Republic, Germany, Hungary and New Zealand, to assess the safety and tolerability of CCX140 in patients with type 2 diabetes. In addition, CCX140 demonstrated biological activity through a dose-dependent decrease in fasting plasma glucose.